Hyaluronic acid gel (Juvéderm) preparations in the treatment of facial wrinkles and folds

Inja Bogdan Allemann, Leslie Baumann, Inja Bogdan Allemann, Leslie Baumann

Abstract

Soft tissue augmentation with temporary dermal fillers is a continuously growing field, supported by the ongoing development and advances in technology and biocompatibility of the products marketed. The longer lasting, less immunogenic and thus more convenient hyaluronic acid (HA) fillers are encompassing by far the biggest share of the temporary dermal filler market. Since the approval of the first HA filler, Restylane, there are at least 10 HA fillers that have been approved by the FDA. Not all of the approved HA fillers are available on the market, and many more are coming. The Juvéderm product line (Allergan, Irvine, CA), consisting of Juvéderm Plus and Juvéderm Ultra Plus, was approved by the FDA in 2006. Juvéderm is a bacterium-derived nonanimal stabilized HA. Juvéderm Ultra and Ultra Plus are smooth, malleable gels with a homologous consistency that use a new technology called "Hylacross technology". They have a high concentration of cross-linked HAs, which accounts for its longevity. Juvéderm Ultra Plus is used for volumizing and correcting deeper folds, whereas Juvéderm Ultra is best for contouring and volumizing medium depth facial wrinkles and lip augmentation. Various studies have shown the superiority of the HA filler products compared with collagen fillers for duration, volume needed, and patient satisfaction. Restylane, Perlane, and Juvéderm are currently the most popular dermal fillers used in the United States.

Figures

Figure 1
Figure 1
Structure of hyaluronic acid.
Figure 2
Figure 2
Before Juvedérm™ to the Marionette lines.
Figure 3
Figure 3
24 hours after Juvedérm™ Ultra to right Marionette line.

References

    1. Cosmetic Surgery National Data Bank Statistics. Los Alamitos (CA): American Society of Aesthetic Plastic Surgery; 2005. [Accessed 2006 Jun 7]. [online] URL: .
    1. Duranti F, Salti G, Bovani B, et al. Injectable hyaluronic acid gel for soft-tissue augmentation: A clinical and histological study. Dermatol Surg. 1998;24:1317.
    1. Smith KC. Practical use of Juvéderm: early experience. Plast Reconstr Surg. 2007;120(Suppl):67S–73S.
    1. [FDA] Food and Drug Administration. Summary of safety and effectiveness data. Rockville (MD): 2006. [Accessed 2006 Aug 23]. [online] URL: .
    1. Baumann LS, Shamban AT, Lupo MP, et al. Juvéderm vs Zyplast, Nasolabial Fold Study Group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg. 2007;33(Suppl 2):S128–35.
    1. Pinsky MA, Thomas JA, Murphy, et al. Juvedérm injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness [poster]. American Society for Aesthetic Plastic Surgery Annual Meeting; New York, NY. April 19–24.2007.
    1. Lupo MP, Smith SR, Thomas JA, et al. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg. 2008;121:289–97.
    1. Moers-Carpi M, Vogt S, Santos BM, et al. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg. 2007;33(Suppl 2):S144–51.
    1. Narins RS, Brandt F, Leyden J, et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003;29:588–95.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する